



Arthritis Foundation, Inc.

Financial Statements
Years Ended December 31, 2018 and 2017

Arthritis Foundation, Inc.

Financial Statements
Years Ended December 31, 2018 and 2017

Arthritis Foundation, Inc.

Contents

Independent Auditor's Report	3-4
Financial Statements	
Statements of Financial Position	6
Statements of Activities	7-8
Statements of Functional Expenses	9-10
Statements of Cash Flows	11
Notes to the Financial Statements	12-29



Tel: 919-754-9370
Fax: 919-754-9369
www.bdo.com

421 Fayetteville Street
Suite 300
Raleigh, NC 27601

Independent Auditor's Report

Board of Directors
Arthritis Foundation, Inc.
Atlanta, GA

We have audited the accompanying financial statements of Arthritis Foundation, Inc. (the "Foundation"), which comprise the statements of financial position as of December 31, 2018 and 2017, and the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Arthritis Foundation, Inc. as of December 31, 2018 and 2017, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter

As discussed in Note 2 to the financial statements, during the year ended December 31, 2018, the Foundation adopted new accounting guidance, Financial Accounting Standards Board Accounting Standards Update 2016-14, *Not-for-Profit Entities (Topic 958) Presentation of Financial Statements of Not-for-Profit Entities*. Our opinion is not modified with respect to this matter.

BDO USA, LLP

June 26, 2019

Financial Statements

Arthritis Foundation, Inc.

Statements of Financial Position

<i>December 31,</i>	2018	2017
Assets		
Cash and cash equivalents	\$ 17,926,748	\$ 19,216,408
Investments	88,029,778	92,291,144
Accounts and notes receivable, net	1,770,842	2,787,700
Contributions receivable, net	17,587,420	19,511,562
Prepaid expenses and other assets	2,251,319	1,859,675
Inventory	65,839	91,721
Beneficial interest in perpetual trusts	43,310,285	46,409,323
Property and equipment, net	4,856,239	5,281,313
Total Assets	\$ 175,798,470	\$ 187,448,846
Liabilities and Net Assets		
Liabilities		
Accounts payable	\$ 1,351,280	\$ 3,443,391
Accrued expenses and other liabilities	9,251,258	7,623,770
Research awards and grants payable	9,899,490	9,335,057
Liabilities under split interest agreements	7,613,428	8,233,093
Debt obligations	-	7,811
Total Liabilities	28,115,456	28,643,122
Net Assets		
Without donor restrictions	40,255,364	45,147,713
With donor restrictions	107,427,650	113,658,011
Total Net Assets	147,683,014	158,805,724
Total Liabilities and Net Assets	\$ 175,798,470	\$ 187,448,846

See the accompanying notes to the financial statements.

Arthritis Foundation, Inc.

Statement of Activities

<i>Years ended December 31,</i>	Without Donor Restrictions	With Donor Restrictions	Total 2018	Total 2017
Revenues, Gains and Public Support				
Direct response marketing contributions	\$ 9,477,509	\$ -	\$ 9,477,509	\$ 10,028,619
Corporate contributions	1,961,157	10,470,993	12,432,150	10,391,577
Personal contributions	1,615,602	1,113,251	2,728,853	2,803,749
Foundations	1,361,370	1,468,419	2,829,789	2,474,671
Memorials	174,586	2,227	176,813	231,529
Other gifts	114,116	65,604	179,720	297,355
Total contributions	14,704,340	13,120,494	27,824,834	26,227,500
Special events - gross income	22,253,066	1,451,250	23,704,316	23,993,237
Less direct donor benefit costs	(4,701,824)	-	(4,701,824)	(4,705,810)
Bequests/planned giving	16,378,329	2,499,730	18,878,059	19,085,219
Total direct public support	48,633,911	17,071,474	65,705,385	64,600,146
Federated campaigns	545,972	450	546,422	599,838
United Way	345,746	-	345,746	400,159
Total indirect public support	891,718	450	892,168	999,997
Contributed goods and services	-	-	-	30,526
Total public support	49,525,629	17,071,924	66,597,553	65,630,669
Government grants	132,821	-	132,821	186,486
Investment return for operations	2,076,247	1,846,431	3,922,678	4,553,663
Conferences, sales, other revenue, gains and losses	9,420,116	13,426	9,433,542	9,345,922
Total other revenue, gains and losses	11,629,184	1,859,857	13,489,041	14,086,071
Net assets released from restrictions	16,413,586	(16,413,586)	-	-
Total Revenues, Gains and Public Support	77,568,399	2,518,195	80,086,594	79,716,740
Expenses				
Research	(13,687,831)	-	(13,687,831)	(12,322,000)
Public health education	(30,348,207)	-	(30,348,207)	(29,672,454)
Professional education and training	(1,359,059)	-	(1,359,059)	(1,869,268)
Patient and community services	(15,962,730)	-	(15,962,730)	(15,812,228)
Fundraising	(10,456,839)	-	(10,456,839)	(10,336,128)
Management and general	(7,019,401)	-	(7,019,401)	(8,885,058)
Total Expenses	(78,834,067)	-	(78,834,067)	(78,897,136)
Change in net assets from operating activities	(1,265,668)	2,518,195	1,252,527	819,604
Non-operating Income				
Net realized and unrealized gains (losses) on investments	(3,802,201)	(6,707,944)	(10,510,145)	9,330,516
Unrealized gain (loss) on beneficial interests in perpetual trusts	-	(2,810,695)	(2,810,695)	1,869,940
Realized gain on the sale of property & equipment	-	-	-	81,418
Change in valuation in split interest agreements	-	770,083	770,083	(333,725)
Net change in pension liabilities	175,520	-	175,520	(234,864)
Change in net assets from non-operating activities	(3,626,681)	(8,748,556)	(12,375,237)	10,713,285
Change in Net Assets	(4,892,349)	(6,230,361)	(11,122,710)	11,532,889
Net Assets, beginning of year	\$ 45,147,713	\$ 113,658,011	\$ 158,805,724	\$ 147,272,835
Net Assets, end of year	\$ 40,255,364	\$ 107,427,650	\$ 147,683,014	\$ 158,805,724

See the accompanying notes to the financial statements.

Arthritis Foundation, Inc.

Statement of Activities

Year ended December 31, 2017	Without Donor Restrictions	With Donor Restrictions	Total
Revenues, Gains and Public Support			
Direct response marketing contributions	\$ 10,028,619	\$ -	\$ 10,028,619
Corporate contributions	1,767,462	8,624,115	10,391,577
Personal contributions	2,323,080	480,669	2,803,749
Foundations	844,528	1,630,143	2,474,671
Memorials	218,614	12,915	231,529
Other gifts	184,965	112,390	297,355
Total contributions	15,367,268	10,860,232	26,227,500
Special events - gross income	22,691,237	1,302,000	23,993,237
Less direct donor benefit costs	(4,705,810)	-	(4,705,810)
Bequests/planned giving	17,673,180	1,412,039	19,085,219
Total direct public support	51,025,875	13,574,271	64,600,146
Federated campaigns	596,537	3,301	599,838
United Way	400,159	-	400,159
Total indirect public support	996,696	3,301	999,997
Contributed goods and services	30,526	-	30,526
Total public support	52,053,097	13,577,572	65,630,669
Government grants	186,486	-	186,486
Investment return for operations	2,651,602	1,902,061	4,553,663
Conferences, sales, other revenue, gains and losses	9,768,237	(422,315)	9,345,922
Total other revenue, gains and losses	12,606,325	1,479,746	14,086,071
Net assets released from restrictions	21,876,199	(21,876,199)	-
Total Revenues, Gains and Public Support	86,535,621	(6,818,881)	79,716,740
Expenses			
Research	(12,322,000)	-	(12,322,000)
Public health education	(29,672,454)	-	(29,672,454)
Professional education and training	(1,869,268)	-	(1,869,268)
Patient and community services	(15,812,228)	-	(15,812,228)
Fundraising	(10,336,128)	-	(10,336,128)
Management and general	(8,885,058)	-	(8,885,058)
Total Expenses	(78,897,136)	-	(78,897,136)
Change in net assets from operating activities	7,638,485	(6,818,881)	819,604
Non-operating Income (Expense)			
Net realized and unrealized gains on investments	3,677,694	5,652,822	9,330,516
Unrealized gain on beneficial interests in perpetual trusts	-	1,869,940	1,869,940
Realized gain on the sale of property & equipment	81,418	-	81,418
Change in valuation in split interest agreements	11,073	(344,798)	(333,725)
Net change in pension liabilities	(234,864)	-	(234,864)
Change in net assets from non-operating activities	3,535,321	7,177,964	10,713,285
Change in Net Assets	11,173,806	359,083	11,532,889
Net Assets, beginning of year	\$ 33,973,907	\$ 113,298,928	\$ 147,272,835
Net Assets, end of year	\$ 45,147,713	\$ 113,658,011	\$ 158,805,724

See the accompanying notes to the financial statements.

Arthritis Foundation, Inc.

Statement of Functional Expenses

Year ended December 31, 2018	Program Services					Supporting Services			Total
	Research	Public Health Education	Professional Education and Training	Patient and Community Services	Total Program Services	Fundraising	Management and General	Total Supporting Services	
Research awards and grants	\$ 10,442,009	\$ 230	\$ 10	\$ 67,645	\$ 10,509,894	\$ 75	\$ 35	\$ 110	\$ 10,510,004
Salaries	1,362,400	11,476,656	574,112	6,963,969	20,377,137	4,731,084	3,428,253	8,159,337	28,536,474
Payroll taxes	78,661	868,966	43,090	507,907	1,498,624	348,499	242,721	591,220	2,089,844
Employee benefits	148,517	1,759,047	97,184	1,165,441	3,170,189	721,717	507,080	1,228,797	4,398,986
Advertising commissions	-	39,370	-	-	39,370	173,186	23,617	196,803	236,173
Professional fees and contract services	377,355	2,947,600	186,204	1,308,881	4,820,040	1,174,733	1,368,632	2,543,365	7,363,405
Supplies	6,412	145,912	9,580	131,629	293,533	48,775	31,912	80,687	374,220
Printing, publications, and artwork	56,722	1,542,757	36,131	319,892	1,955,502	138,059	67,611	205,670	2,161,172
Membership/direct response marketing	200,861	5,376,563	105,452	140,603	5,823,479	1,811,076	120,517	1,931,593	7,755,072
Postage, shipping, and delivery	76,221	1,800,912	42,918	195,009	2,115,060	105,706	72,994	178,700	2,293,760
Telephone	15,635	113,211	30,849	97,591	257,286	141,716	316,565	458,281	715,567
Occupancy	144,177	1,176,904	41,944	955,783	2,318,808	335,116	160,644	495,760	2,814,568
Insurance	102,063	176,393	28	261,196	539,680	17,217	11,436	28,653	568,333
Staff travel	101,497	736,413	73,538	965,333	1,876,781	264,250	225,578	489,828	2,366,609
Meetings and conferences	88,192	605,400	78,180	1,557,899	2,329,671	94,644	90,853	185,497	2,515,168
Equipment lease and maintenance	101,136	213,707	20,403	284,017	619,263	103,962	224,868	328,830	948,093
Membership dues and subscriptions	22,993	56,831	(4,108)	69,023	144,739	33,500	18,531	52,031	196,770
Specific assistance to individuals	-	-	-	10,528	10,528	-	-	-	10,528
Advertising	29,417	324,955	15,901	70,134	440,407	69,553	36,209	105,762	546,169
Depreciation	164,429	283,183	-	420,207	867,819	27,405	18,270	45,675	913,494
Uncollectible receivables	3,096	328,020	1,876	7,164	340,156	9,942	3,681	13,623	353,779
Other	166,038	375,177	5,767	462,879	1,009,861	106,624	49,394	156,018	1,165,879
Total Expenses	\$ 13,687,831	\$ 30,348,207	\$ 1,359,059	\$ 15,962,730	\$ 61,357,827	\$ 10,456,839	\$ 7,019,401	\$ 17,476,240	\$ 78,834,067

See the accompanying notes to the financial statements.

Arthritis Foundation, Inc.

Statement of Functional Expenses

Year ended December 31, 2017	Program Services					Supporting Services				Total
	Research	Public Health Education	Professional Education and Training	Patient and Community Services	Total Program Services	Fundraising	Management and General	Total Supporting Services		
Research awards and grants	\$ 9,780,919	\$ 31,730	\$ 1,379	\$ 46,417	\$ 9,860,445	\$ 5,017	\$ 1,317	\$ 6,334	\$ 9,866,779	
Salaries	1,229,948	10,992,970	805,814	7,090,638	20,119,370	4,312,975	3,430,222	7,743,197	27,862,567	
Payroll taxes	78,910	864,311	64,102	559,928	1,567,251	330,323	257,445	587,768	2,155,019	
Employee benefits	167,485	1,763,979	134,098	1,142,394	3,207,956	671,704	529,401	1,201,105	4,409,061	
Advertising commissions	-	158,738	-	52,913	211,651	-	-	-	211,651	
Professional fees and contract services	268,965	2,305,152	258,355	1,313,054	4,145,526	1,243,006	2,515,093	3,758,099	7,903,625	
Supplies	11,484	233,930	17,283	166,357	429,054	59,400	48,106	107,506	536,560	
Printing, publications, and artwork	44,608	1,045,277	43,543	693,952	1,827,380	94,915	58,260	153,175	1,980,555	
Membership/direct response marketing	106,178	5,390,632	60,203	72,519	5,629,532	1,894,914	58,398	1,953,312	7,582,844	
Postage, shipping, and delivery	81,208	1,299,476	55,347	874,224	2,310,255	93,418	92,182	185,600	2,495,855	
Telephone	20,706	150,122	52,104	134,185	357,117	218,309	535,577	753,886	1,111,003	
Occupancy	126,483	1,600,305	134,478	1,020,029	2,881,295	459,347	321,151	780,498	3,661,793	
Insurance	111,121	247,574	6,279	83,213	448,187	64,807	76,159	140,966	589,153	
Staff travel	67,084	820,795	76,673	692,574	1,657,126	224,678	219,261	443,939	2,101,065	
Meetings and conferences	62,043	992,466	67,663	1,194,623	2,316,795	84,201	68,270	152,471	2,469,266	
Equipment lease and maintenance	129,451	351,073	31,424	161,504	673,452	167,508	306,924	474,432	1,147,884	
Membership dues and subscriptions	20,198	74,673	3,636	42,851	141,358	23,220	22,250	45,470	186,828	
Specific assistance to individuals	-	-	-	12,061	12,061	-	-	-	12,061	
Advertising	15,797	253,483	24,507	50,087	343,874	55,753	28,572	84,325	428,199	
Depreciation	185,428	409,894	9,759	136,631	741,712	107,353	126,872	234,225	975,937	
Uncollectible receivables	62,615	147,670	2,591	47,856	260,732	77,389	-	77,389	338,121	
Other	(248,631)	538,204	20,030	224,218	533,821	147,891	189,598	337,489	871,310	
Total Expenses	\$ 12,322,000	\$ 29,672,454	\$ 1,869,268	\$ 15,812,228	\$ 59,675,950	\$ 10,336,128	\$ 8,885,058	\$ 19,221,186	\$ 78,897,136	

See the accompanying notes to the financial statements.

Arthritis Foundation, Inc.

Statements of Cash Flows

<i>Years ended December 31,</i>	2018	2017
Cash flows from operating activities:		
Change in net assets	\$ (11,122,710)	\$ 11,532,889
Adjustments to reconcile change in net assets to net cash and cash equivalents used in operating activities:		
Depreciation	913,494	975,938
Gain on sale of property and equipment	-	81,418
Net realized and unrealized losses (gains) on investments	9,740,061	(9,330,516)
Net change in valuation of investments	(1,848,287)	333,725
Change in operating assets and liabilities:		
Accounts and notes receivable	1,016,858	(22,095)
Contributions receivable	1,924,142	(4,758,427)
Prepaid expenses and other assets	(391,644)	(401,162)
Inventory	25,882	39,307
Beneficial interests in perpetual trusts	3,099,038	(1,869,940)
Accounts payable	(2,092,111)	170,269
Accrued expenses and other liabilities	1,627,488	772,374
Research awards and grants payable	564,433	852,015
Liabilities under split interest agreements	(619,665)	(365,992)
Net cash provided by (used in) operating activities	2,836,979	(1,990,197)
Cash flows from investing activities:		
Purchase of property and equipment	(488,420)	(634,064)
Net proceeds from sale of property and equipment	-	107,004
Transfer investment cash	-	4,000,000
Purchase of investments	(32,725,056)	(102,028,237)
Proceeds from sale of investments	29,094,648	103,751,705
Net cash (used in) provided by investing activities	(4,118,828)	5,196,408
Cash flows from financing activities:		
Payments on capital lease obligations	(7,811)	(34,426)
Net cash used in financing activities	(7,811)	(34,426)
Net (decrease) increase in cash and cash equivalents	(1,289,660)	3,171,785
Cash and cash equivalents, beginning of year	19,216,408	16,044,623
Cash and cash equivalents, end of year	\$ 17,926,748	\$ 19,216,408
Supplemental information:		
Interest paid	\$ -	\$ 1,424

See the accompanying notes to the financial statements.

Arthritis Foundation, Inc.

Notes to Financial Statements

1. Description of Organization

The Arthritis Foundation, Inc. (the "Foundation") is a voluntary health agency seeking to improve lives through leadership in the prevention, control and cure of arthritis and arthritis-related diseases. Major funding sources are from direct public contributions and bequests. The Foundation provides public health education and community service programs along with supporting arthritis-related research and influencing public policy regarding research funding, access to care and government funding of arthritis-related public health programs. The Arthritis Foundation operates under Section 501(c)(3) of the Internal Revenue Code.

2. Summary of Significant Accounting Policies

A summary of the significant accounting policies consistently applied in the preparation of the accompanying financial statements follows.

Basis of Accounting

The financial statements of the Foundation have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("GAAP").

Basis of Presentation

The Foundation classifies its net assets and revenues, expenses, gains and losses on the existence or absence of donor-imposed restrictions. Accordingly, net assets of the Foundation and changes therein are classified and reported as follows:

Net assets without donor restrictions - Net assets that are not subject to donor-imposed stipulations.

Net assets with donor restrictions - Net assets subject to stipulations imposed by donor and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Foundation or by the passage of time. Other donor restrictions are perpetual in nature, where by the donor has stipulated the funds be maintained in perpetuity.

Revenues are reported as increases in net assets without donor restrictions unless the use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor imposed restrictions unless their use is restricted by explicit donor stipulation or by law. Expirations of temporary restrictions on net assets with donor restrictions (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as reclassifications between the applicable classes of net assets.

Operating results in the statements of activities reflect all transactions increasing and decreasing net assets except those that the Foundation defines as non-operating. Non-operating includes all investment returns in excess of those classified as operating by the spending policy, unrealized gains and losses from operating accounts, unrealized gains and losses on beneficial interests in perpetual trusts, changes in valuation of split interest agreements, and net changes in pension liabilities.

Arthritis Foundation, Inc.

Notes to Financial Statements

Concentrations of Risk

Financial instruments which potentially subject the Foundation to concentrations of credit and market risk consist principally of cash and cash equivalents and marketable securities held at creditworthy financial institutions. At December 31, 2018 and 2017, the Foundation's uninsured cash balance totaled \$15,223,246 and \$12,368,008, respectively. Cash and cash equivalents are maintained at large multi-state financial institutions and credit exposure is limited to the amount of deposits at any one institution in excess of the federally insured limit. The Foundation has not experienced any losses in such accounts. The Foundation's marketable securities do not represent significant concentrations of market risk as the marketable securities portfolio is diversified among a variety of issuers.

Investment securities and real estate held as investments that are not publicly traded are exposed to several risks, such as interest rate, market, liquidity and credit risks. Due to the level of risk associated with certain investments, it is at least reasonably possible that changes in the values of these investments will occur in the near term and that such change could materially affect the amounts reported in the Foundation's statement of financial position and statement of activities.

Cash and Cash Equivalents

The Foundation's cash equivalents are highly liquid investments with an original maturity of three months or less at the date of purchase. Because of the short maturity of these financial instruments, the carrying value approximates the fair value.

Investments

Investments in equity securities with readily determinable fair values and all investments in debt securities are stated at fair value. The cost assigned to investments received by gift is the fair value at the date the gift is received. Purchases and sales of securities are reflected on a trade-date basis. Gains and losses on sales of securities are based on cost (cost of securities if purchased or the fair market value at the date of gift if received by donation). Dividend and interest income is recorded on the accrual basis. In accordance with the policy of stating investments at fair value, the net change in unrealized appreciation or depreciation for the year is reflected in the statement of activities. Investment return is presented net of investment fees.

Accounts Receivable

Accounts receivable consist of exchange transactions primarily related to government grants and sales and service fees and are stated at unpaid balances, less an allowance for doubtful accounts when deemed necessary. Receivables are written off when management believes they will not be collected. Amounts are considered past due if they are not received within one year after the expected payment date.

Arthritis Foundation, Inc.

Notes to Financial Statements

Contributions Receivable

Contributions, including unconditional promises to give, are recorded at the date of gift. Unconditional promises to give that are expected to be collected within one year are recorded at their net realizable value. Bequests are recorded as revenue at the time an unassailable right to the gift has been established and the proceeds are measurable in amount. Long-term promises to give are initially recorded at fair value using the income approach using discount rates commensurate with the risk involved at the date of donation. An allowance for doubtful accounts on outstanding contributions receivable balances is recorded when deemed necessary based upon historical trends, current market risk assessments and specific donor considerations. Receivables are written off when management believes they will not be collected. Amounts are considered past due if they are not received within one year after the expected payment date.

Conditional promises to give are not recognized in the Statements of Activities until the conditions are substantially met. There were no conditional promises to give for the years ended December 31, 2018 and 2017.

Inventory

Inventory consists of educational and campaign materials which are stated at lower of cost or market. Cost is determined by the weighted average method.

Split Interest Agreements

The Foundation's split interest agreements are recorded as follows:

Charitable Gift Annuities and Other Split Interest Agreements under which the Foundation is the Trustee - Such amounts are valued at the date of donation using the income method and discount rates commensurate with the risks involved. Discount rates range from three to ten percent. Charitable gift annuities are amortized over their life although changes may be made based on a change in the life expectancy of the donor. Gift annuity assets are included in investments and amounts due to the donor are included in liabilities under split interest agreements.

Beneficial Interests in Perpetual Trusts - The Foundation is the beneficiary of various trusts created by donors, the assets of which are not in the possession of the Foundation. The Foundation has legally enforceable rights or claims to such assets including the right to income therefrom. Under the perpetual trust arrangement, the Foundation has recorded the asset and recognized permanently restricted contribution revenue at the fair value of its beneficial interest in the trust assets. Distributions received on the trust assets are recorded as investment income in the statement of activities unless otherwise restricted by the donor. Subsequent changes in fair value of the beneficial interest in the trust assets are recorded as net unrealized gains or losses on beneficial interest in perpetual trusts in the net asset with donor restrictions class.

Arthritis Foundation, Inc.

Notes to Financial Statements

Property and Equipment

Property and equipment are recorded at cost. Donated assets are capitalized at the estimated fair market value at date of receipt. Depreciation is provided on the straight-line method over the estimated useful lives of the assets. The cost of maintenance and repairs is expensed when incurred; significant renewals and betterments are capitalized. Estimated useful lives are ten to thirty years for buildings and improvements, the lesser of the lease term or three to ten years for leasehold improvements and three to five years for furniture and other equipment.

Impairment of Long-Lived Assets

The Foundation reviews asset carrying amounts whenever events or circumstances indicate that such carrying amounts may not be recoverable. When considered impaired, the carrying amount of the asset is reduced to its current fair value. There were no long-lived assets that were impaired during the years ended December 31, 2018 and 2017.

Fair Value of Financial Instruments

The carrying amounts of cash and accounts receivable, which qualify as financial assets and accounts payable, and accrued expenses, which qualify as financial liabilities, approximate fair value due to the relative terms of these financial instruments.

The carrying values, which approximate fair value, of investments, beneficial interests in trusts, and investments in remainder interest trusts are determined as described in Note 5.

The carrying amount of the notes payable approximates fair value since they bear interest at variable rates which approximate current market rates for notes with similar maturities and credit quality.

The carrying amounts of annuities payable and contributions receivable approximate fair value since these instruments are recorded at net present value.

Research Awards and Grants Payable

Awards and grants are recorded as expenses in the year in which the award is made. The terms of research awards and grants are from one to three years with continuation of grants subject to certain performance requirements.

Functional Allocation

The costs of providing the Foundation's various programs and supporting services have been summarized on a functional basis. Accordingly, certain costs have been allocated among the programs and supporting services benefited. Such allocations are determined by management on an equitable basis. The Foundation uses a weighted-average methodology to allocate occupancy, interest, insurance and depreciation cost. Salaries are allocated on the basis of time and effort.

Arthritis Foundation, Inc.

Notes to Financial Statements

Contributed Goods and In-Kind Services

Contributed goods and services are reflected as both contribution revenue and expenses in the accompanying statement of activities at their estimated fair value at date of receipt. Existing contributed goods and gifts of property and equipment are reflected as support without donor restrictions unless explicit donor stipulations specify how the donated goods must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as support with donor restrictions. Absent explicit donor stipulations about how long those long-lived assets must be maintained, the Foundation reports expirations of donor restrictions when the donated or acquired long-lived assets are placed in service.

The Foundation receives services from a large number of volunteers who give significant amounts of their time to the Foundation's programs, fundraising campaigns and management. The contributions of services are recognized if the services received (a) create or enhance nonfinancial assets or (b) require specialized skills that are provided by individuals possessing those skills and would typically need to be purchased if not provided. Generally, such services include research grant application reviews, advertising, consulting, and printing services and other services that meet the criteria for recognition as contributed services. No amounts were recorded as revenue and expense for donated services and assets for the years ended December 31, 2018 and 2017.

Income Taxes

The Foundation is exempt from Federal income tax as an organization described in Section 501(c)(3) of the Internal Revenue Code. With respect to any unrelated business income generated by the Foundation, it records income taxes using the liability method under which deferred tax assets and liabilities are determined based on the differences between the financial accounting and tax bases of assets and liabilities. Deferred tax assets or liabilities at the end of each period are determined using the currently enacted tax rate expected to apply to taxable income in the period that the deferred tax asset or liability is expected to be realized or to be settled. As of December 31, 2018, and 2017, the Foundation had no deferred tax assets or liabilities or any uncertain tax positions.

Use of Estimates

Management of the Foundation has made a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities to prepare the financial statements in conformity with GAAP. Actual results could differ from these estimates.

Accounting Pronouncements Issued but Not Yet Adopted

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, *Revenue from Contracts with Customers (Topic 606)*. This update, along with ASU 2016-08, *Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net)*, ASU 2016-10, *Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing* and ASU 2016-12, *Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients*, establishes a comprehensive revenue recognition standard. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for

Arthritis Foundation, Inc.

Notes to Financial Statements

those goods or services. ASU 2014-09 is effective for the Foundation's fiscal year ending December 31, 2019. Earlier adoption would have been permitted subject to certain limitations. The amendments in this update are required to be applied retrospectively to each prior reporting period presented or with the cumulative effect being recognized at the date of initial application. Management is currently evaluating the impact of these ASUs on their financial statements.

In February 2016, the FASB issued Accounting Standards Update 2016-02, *Leases (Topic 842)* ("ASU 2016-02"), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis, and a right-of-use asset, which is an asset that represents the lessee's right to use, or control the use of, a specified asset for the lease term. Certain targeted improvements were made to align, where necessary, lessor accounting with the lessee accounting model and Topic 606, *Revenue from Contracts with Customers*. Early application is permitted for all public business entities and all nonpublic business entities upon issuance. Lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. Lessees and lessors may not apply a full retrospective transition approach. Management estimates that if the new standard had been adopted as of December 31, 2018, it would have resulted in recording right-to-use lease assets and related lease liabilities for the discounted value of future minimum lease payments on its existing operating leases. ASU 2016-02 is effective for annual periods beginning after December 15, 2019. The full financial statement impact of such changes and the implementation of ASU 2016-02 is still being evaluated by management.

In June 2018, the FASB issued ASU 2018-08, *Not-for-Profit Entities (Topic 958) - Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made* ("ASU 2018-08"). Early application is permitted for all public business entities and all nonpublic business entities upon issuance. ASU 2018-08 clarifies and improves current guidance by providing criteria for determining whether the resource provider is receiving commensurate value in return for the resources transferred which, depending on the outcome, determines whether the organization follows contribution guidance or exchange transaction guidance in the revenue recognition and other applicable standards. ASU 2018-08 also provides a more robust framework for determining whether a contribution is conditional or unconditional, and for distinguishing a donor-imposed condition from a donor-imposed restriction. The ASU is effective for transactions in which the entity serves as the resource recipient to annual periods beginning after December 15, 2018. The ASU is effective for transactions in which the entity serves as a resource provider to annual periods beginning after December 15, 2019. The full financial statement impact of such changes and the implementation of ASU 2018-08 is still being evaluated by management and expect it to have minimal impact on the timing of contributions received and contributions made.

Recently Adopted Authoritative Guidance

During the year ended December 31, 2018, the Foundation adopted ASU 2016-14, *Not-for-Profit Entities (Topic 958): Presentation of Financial Statements of Not-for-Profit Entities* ("ASU 2016-14"). This guidance is intended to improve the net asset classification requirements and the information presented in the financial statements and notes about a not-for-profit entity's liquidity, financial performance, and cash flows. Main provisions of this guidance include: presentation of two

Arthritis Foundation, Inc.

Notes to Financial Statements

classes of net assets versus the previously required three; recognition of capital gifts for construction as a net asset without donor restrictions when the associated long-lived asset is placed in service; and recognition of underwater endowment funds as a reduction in net assets with donor restrictions. The guidance also enhances disclosures for board designated amounts, composition of net assets without donor restrictions, liquidity, and expenses by both their natural and functional classification. Net assets previously classified as unrestricted as of and for the year ended December 31, 2017 have been retroactively reclassified as net assets without donor restrictions. In addition, net assets previously classified as temporarily or permanently restricted as of and for the year ended December 31, 2017 have been retroactively reclassified as net assets with donor restrictions. The Foundation held no underwater endowment funds as of December 31, 2017.

3. Liquidity and Availability of Resources

As of December 31, 2018, financial assets available within one year for general expenditures are as follows:

	Financial Assets		
	Available	Unavailable	Total
Financial assets			
Cash and cash equivalents	\$ 17,326,333	\$ 600,415	\$ 17,926,748
Investments	33,511,456	54,518,322	88,029,778
Accounts and notes receivable, net	1,770,842	-	1,770,842
Contributions receivable, net	15,181,627	2,405,793	17,587,420
Beneficial interest in perpetual trusts	-	43,310,285	43,310,285
Endowment spend appropriations	1,958,980	-	1,958,980
Financial assets available/unavailable to meet cash needs for general expenditures within one year	\$ 69,749,238	\$100,834,815	\$170,584,053

The Foundations' financial assets have been reduced by amounts not available for general use due to donor imposed restrictions within one year of the balance sheet date, and amounts set aside for long-term investing in endowment funds.

The Foundation's endowment consists of donor-restricted endowment funds as well as funds specified by donors as restricted for research and specific programs. Therefore these funds are not available for general expenditures. As described in Note 6, without specific Board action the endowment funds have a spending rate of 4 percent. Approximately \$1,959,000 of appropriations from the endowment fund will be available within the next 12 months.

As part of the Foundation's liquidity management, it structures its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Beginning third quarter 2019, cash in excess of daily requirements will be invested in short-term investments and money market funds.

Arthritis Foundation, Inc.

Notes to Financial Statements

4. Investments

Investments at fair value were as follows at:

<i>December 31,</i>	2018	2017
Marketable securities		
Investment accounts		
Common stock	\$ 111,064	\$ -
Domestic equity mutual funds	27,127,101	25,378,307
Fixed income mutual funds	23,658,993	23,523,261
International equity mutual funds	17,731,180	21,127,094
Preferred stock	1,000	1,000
Alternative investments	715,315	2,273,709
Hedge funds	3,005,626	3,425,544
Real estate funds	2,191,262	2,813,532
Other commodities	1,921,011	448,606
International common stock	20,743	-
Other - principally money market and other mutual funds	259,769	25,349
Total marketable securities	76,743,064	79,016,402
Split interest agreements		
Real estate funds	342,878	514,144
Corporate notes and bonds	372,421	893,752
Domestic equity mutual funds	4,059,386	5,266,686
Fixed income mutual funds	4,188,612	3,860,315
International equity mutual funds	2,323,417	2,739,845
Total split interest agreements	11,286,714	13,274,742
Total investments	\$ 88,029,778	\$ 92,291,144

Arthritis Foundation, Inc.

Notes to Financial Statements

5. Fair Value Measurements

In accordance with GAAP, fair value measurement establishes a framework for measuring fair value and expands disclosures about fair value measurements.

This standard provides a consistent definition of fair value which focuses on an exit price between market participants in an orderly transaction as prescribed by GAAP. The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information and establishes a three-level hierarchy for fair value measurements based on the transparency of information used in the valuation of an asset or liability as of the measurement date. The standard describes three levels of inputs that may be used to measure fair value:

Level I - Quoted prices for identical instruments in active markets. This category includes domestic and international debt and equity securities that are traded in an active exchange market, as well as U.S. Treasury securities.

Level II - Inputs other than quoted prices included in Level I that are observable, either directly or indirectly. Such inputs may include quoted prices for similar assets, observable inputs other than quoted prices (interest rates, yield curves, etc.), or inputs derived principally from or corroborated by observable market data by correlation or other means. This category includes certain U.S. Government and agency mortgage-backed debt securities and corporate debt securities that are valued based on market prices for similar and actively traded investments. This category also includes alternative investments that are valued at net asset value ("NAV") per share for which the Foundation has the ability to redeem its investment at the measurement date.

Level III - Inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability. The inputs reflect the Foundation's assumptions based on the best information available in the circumstances. This category includes split interest agreements and beneficial trusts for which the Foundation is not the trustee. The trusts are valued based on the values of the underlying investments in the trust which are established by the trustee using valuation methods that are appropriate for the investments in the trusts.

Quantitative information related to valuation inputs for Level III assets is not available since the value of the trusts that was provided by the trustees was used without adjustment. On an annual basis, Foundation management evaluates the return received from the trusts against the value of its portion of the trusts for reasonableness as compared with current market returns. Management believes that the sensitivity in the fair value measurement of the beneficial interests is related to market fluctuations, as the investments held in the trusts are primarily marketable securities.

Arthritis Foundation, Inc.

Notes to Financial Statements

The following table summarizes the valuation of the Foundation's investments, split interest agreements and beneficial interests in perpetual trusts by the above hierarchy levels as of December 31:

	2018			
	Level I	Level II	Level III	Total
Marketable securities				
Common stocks	\$ 111,064	\$ -	\$ -	\$ 111,064
Domestic equity mutual funds	31,186,487	-	-	31,186,487
Fixed income mutual funds	27,847,605	-	-	27,847,605
International equity mutual funds	20,054,597	-	-	20,054,597
Preferred stock	1,000	-	-	1,000
Alternative investments	715,315	-	-	715,315
Hedge funds	3,005,626	-	-	3,005,626
Real estate funds	2,534,140	-	-	2,534,140
Corporate notes and bonds	372,421	-	-	372,421
Other commodities	1,920,881	-	130	1,921,011
International common stock	20,743	-	-	20,743
Other - principally money market and other mutual funds	259,769	-	-	259,769
Total marketable securities	88,029,648	-	130	88,029,778
Beneficial interests in perpetual trusts	-	-	43,310,285	43,310,285
Total	\$ 88,029,648	\$ -	\$ 43,310,415	\$ 131,340,063

	2017			
	Level I	Level II	Level III	Total
Marketable securities				
Domestic equity mutual funds	\$ 30,644,993	\$ -	\$ -	\$ 30,644,993
Fixed income mutual funds	26,263,107	-	-	26,263,107
International equity mutual funds	24,987,409	-	-	24,987,409
Preferred stock	1,000	-	-	1,000
Alternative investments	2,273,709	-	-	2,273,709
Hedge funds	3,425,544	-	-	3,425,544
Real estate funds	3,327,675	-	-	3,327,675
Other commodities	1,342,358	-	-	1,342,358
Other commodities	25,349	-	-	25,349
Total marketable securities	92,291,144	-	-	92,291,144
Beneficial interests in perpetual trusts	-	-	46,409,323	46,409,323
Total	\$ 92,291,144	\$ -	\$ 46,409,323	\$ 138,700,467

Arthritis Foundation, Inc.

Notes to Financial Statements

The following table summarizes the Foundation's Level III reconciliation for the beneficial interests in perpetual trusts:

<i>Years ended December 31,</i>	2018	2017
Beginning balance	\$ 46,409,323	\$ 44,539,383
Decrease in beneficial interest in perpetual trust	-	(197,563)
Net unrealized (losses) gains	(3,099,038)	2,067,503
Ending balance	\$ 43,310,285	\$ 46,409,323

With respect to valuation methodologies at December 31, 2018 and 2017, to the extent that the Foundation directly owns and controls the investment valuation is based on unadjusted quoted prices for identical assets in active markets that the Foundation can access. For other investments, predominately "alternative investments" (including private equity, alternative hedge strategies and real assets), the Foundation utilizes the net asset value ("NAV") reported by each of the alternative funds and external investment managers as a practical expedient for determining the fair value of the investment. These investments are redeemable at NAV under the original terms of the agreements and operations of the underlying funds. However, it is possible that these redemption rights may be restricted or eliminated by the funds in the future in accordance with the underlying fund agreements. Due to the nature of the investments held by these funds, changes in market conditions and the economic environment may significantly impact the NAV of the funds and, consequently, the fair value of the Foundation's interests in the funds. Furthermore, changes to the liquidity provisions of the funds may significantly impact the fair value of the Foundation's interest in the funds.

6. Endowment Funds

The Foundation's endowment consists of a number of individual funds established for research, specific programs and operations.

The Foundation understands the law as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. The Foundation classifies as net assets with donor restrictions (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment and (c) accumulations to the permanent endowment made in accordance with the direction of applicable donor gift instrument at the time the accumulation is added to the fund.

The remaining portion of donor-restricted endowment funds in excess of the original fair value are classified as net assets with donor restrictions until those amounts are appropriated for expenditure in a manner consistent with the standard of prudence prescribed by the Uniform Prudent Management of Institutional Funds Act ("UPMIFA").

Arthritis Foundation, Inc.

Notes to Financial Statements

In accordance with UPMIFA, the Foundation considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

1. The duration and preservation of the fund
2. The purpose of the Foundation or the donor-restricted endowment fund
3. General economic conditions
4. The possible effects of inflation and deflation
5. The expected total return from income and the appreciation of investments
6. Other resources of the Foundation
7. The investment policy of the Foundation

If the market value of any fund classified as net assets with donor restrictions at year-end is below the amount determined to be permanently restricted, the deficit, which cannot be funded from restricted unspent earnings of the fund, is reported as a reduction in net assets with donor restrictions. There were no such deficiencies for the years ended December 31, 2018 and 2017.

The primary long-term financial objective for the Foundation's endowment is to preserve the real (inflation-adjusted) purchasing power of endowment assets and income after accounting for endowment spending, inflation and costs of portfolio management. Performance of the overall endowment against this objective is measured over rolling periods of one, three and five years. The endowments shall be managed to optimize the long run total rate of return on invested assets, assuming a prudent level of risk. The goal for this rate of return is one that funds the Foundation's existing spending policy and allows sufficient reinvestment to grow the endowment principal at a rate that exceeds inflation (as measured by the Consumer Price Index). Over the short term, the return for each element of the endowment portfolio should match or exceed each of the returns for the broader capital markets in which assets are invested.

Foundation policy requires endowment assets to be governed by a spending policy that seeks to distribute a specific payout rate of the endowment base to support the Foundation's programs. The endowment base is defined as a three-year moving average of the market value of the total endowment portfolio (calculated as of the last day of December for the prior three years). Without specific Board action to either increase or decrease the payout rate, the Foundation's annual investment income payout distribution is calculated at a rate of four percent of the rolling three year average fair market value of the investments plus amounts paid for share on investment income. The policy allows for a greater predictability of spendable income for budgeting purposes and for gradual steady growth for the support of operations by the endowment.

In addition, the policy minimizes the probability of invading the principal over the long-term. Spending in a given year reduces the unit value of each endowment element by the payout percentage. In no case are funds designated as true endowment reduced below their initial unit value. In the case of short-term declines in the market value of the endowment pool of funds, the overall spending rate may be calculated below designated payout percentage in order to maintain the original unit value of certain elements of the true endowment. Growth of the unit values over time should allow for spending of principal, without drawing from the original corpus of a particular gift.

Arthritis Foundation, Inc.

Notes to Financial Statements

The endowment is divided into three broad asset classes: equity fund, fixed income fund and cash or near-cash fund. The purpose of dividing the endowment fund in this way is to ensure that the optimal long-term return is achieved given the Foundation's risk preference. The endowment is diversified both by asset class (equity, fixed income and cash) and within asset class (large capitalization stocks, small capitalization stocks, U.S. Treasury bonds, corporate bonds, etc.). The purpose of diversification is to provide reasonable assurance that no single security or class of securities has a disproportionate impact on the total endowment and to reduce the overall risk and volatility of the entire portfolio. The total endowment is monitored on a continual basis for consistency of investment philosophy, return relative to objectives, and asset allocation with respect to target percentages. There were no endowment net assets without donor restrictions for the years ended December 31, 2018 and 2017.

The composition of and changes to donor restricted endowment net assets for the years ended December 31, 2018 and 2017 are as follows:

	With Donor Restrictions	Total
Endowment net assets, January 1, 2017	\$ 42,824,792	\$ 42,824,792
Additions	198,073	198,073
Investment return income	1,040,500	1,040,500
Net appreciation (realized and unrealized)	7,267,588	7,267,588
Total investment return	8,506,161	8,506,161
Appropriation of endowment assets for expenditure	(1,846,646)	(1,846,646)
Endowment net assets, December 31, 2017	\$ 49,484,307	\$ 49,484,307
Additions	313,945	313,945
Investment return income	934,692	934,692
Net depreciation (realized and unrealized)	(5,628,726)	(5,628,726)
Total investment additions	(4,380,089)	(4,380,089)
Appropriation of endowment assets for expenditure	(1,958,980)	(1,958,980)
Endowment net assets, December 31, 2018	\$ 43,145,238	\$ 43,145,238

Arthritis Foundation, Inc.

Notes to Financial Statements

7. Contributions Receivable

The Foundation had the following contributions receivable at:

<i>December 31,</i>	2018	2017
Amounts due in:		
Less than one year	\$ 15,494,838	\$ 19,119,683
One to five years	2,405,793	1,134,000
Gross contributions receivable	17,900,631	20,253,683
Allowance for doubtful accounts	(209,809)	(723,569)
Unamortized present value discount	(103,402)	(18,552)
Contributions receivable, net	\$ 17,587,420	\$ 19,511,562

Discounts on contributions receivable were calculated at the date of donation using rates commensurate with the risks involved (1% to 9%).

8. Split Interest Agreements and Beneficial Interests in Perpetual Trusts

The Foundation had the following interests at:

<i>December 31,</i>	2018	2017
Split interest agreements (the Foundation is the trustee)		
Charitable remainder trusts ("CRTs")	\$ 2,957,493	\$ 3,423,423
Gift annuity fund	8,288,830	9,608,697
Pooled income fund	483,657	503,993
Split interest agreements (included in cash and investments)	11,729,980	13,536,113
CRTs (the Foundation is not the trustee)	4,860,730	6,172,001
Perpetual trusts (the Foundation is not the trustee)	38,449,555	40,237,322
Total	\$ 55,040,265	\$ 59,945,436

These assets are reported on the statement of financial position and are valued at estimated fair-value. Liabilities under split interest agreements for which the Foundation is the trustee were \$7,613,428 and \$8,233,093 at December 31, 2018 and 2017, respectively, and were valued at the date of donation using the income approach at discount rates commensurate with the risk involved (between three and 10%). They are being amortized over the terms of the obligations.

Adjustments are made to the value of the split interest agreements when there are changes in the life expectancy of the donor.

Arthritis Foundation, Inc.

Notes to Financial Statements

9. Property and Equipment

Property and equipment consisted of the following at:

<i>December 31,</i>	2018		2017	
Land	\$	635,651	\$	635,651
Buildings and improvements		2,501,825		2,501,825
Leasehold improvements		2,593,436		2,604,394
Furniture and other equipment		4,141,601		3,763,976
Total property and equipment		9,872,513		9,505,846
Accumulated depreciation		(5,016,274)		(4,224,533)
Property and equipment, net	\$	4,856,239	\$	5,281,313

Depreciation expense was \$913,494 and \$975,937 for the years ended December 31, 2018 and 2017, respectively.

10. Debt Obligations

Capital Leases

The Foundation has leased various assets, primarily office equipment, with lease terms approximating the useful lives of the assets. As a result, the present value of the remaining future minimum lease payments are recorded as capitalized lease assets and related notes payable. Assets under capital leases (net of accumulated depreciation) at December 31, 2018 and 2017 were \$0 and \$16,358, respectively, and are included in property and equipment on the accompanying statements of financial position. There were no capital lease obligations outstanding at December 31, 2018.

11. Joint Costs

In 2018 and 2017, the Foundation incurred joint costs of \$5,908,626 and \$6,285,835, respectively, for informational materials and activities that included fundraising appeals, such as the Foundation's direct mail. Joint costs were allocated as follows:

<i>December 31,</i>	2018		2017	
Public health education	\$	4,254,211	\$	4,525,801
Fundraising		1,654,415		1,760,034
Total joint costs	\$	5,908,626	\$	6,285,835

Arthritis Foundation, Inc.

Notes to Financial Statements

12. Net Assets - With Donor Restrictions

Net assets with donor restrictions were available for the following purposes at:

<i>December 31,</i>	2018	2017
Purpose restricted:		
Programs, scholarships, training and projects	\$ 18,501,278	\$ 18,458,214
Research	6,494,907	7,830,995
Time restricted	3,673,879	7,137,393
Net assets with donor restrictions subject to expenditure for specified purpose and passage of time	\$ 28,670,064	\$ 33,426,602

Net assets with donor restrictions consisted of the following with the investment income to be used for:

<i>December 31,</i>	2018	2017
Research	\$ 34,056,761	\$ 33,368,663
Education	3,398,473	3,866,459
Operations	2,651,704	2,651,704
Scholarship	105,000	5,000
Programs	96,093	102,261
Beneficial interests in perpetual trusts	38,449,555	40,237,322
Net assets with donor restrictions to be held in perpetuity	78,757,586	80,231,409

Net assets with donor restrictions released from restrictions consisted of the following:

<i>Year ended December 31,</i>	2018	2017
Programs, scholarships, training and projects	\$ 8,487,310	\$ 11,753,986
Research	3,265,179	5,967,713
Time releases	4,661,097	4,154,500
Total net assets with donor restrictions released from restrictions	\$ 16,413,586	\$ 21,876,199

Arthritis Foundation, Inc.

Notes to Financial Statements

13. Operating Leases

Rental expense for Foundation office space was \$2,617,149 and \$3,435,399 for the years ended December 31, 2018 and 2017, respectively. Lease agreements having an original term of more than one year expire on various dates through 2026.

Total future minimum lease payments were as follows at December 31, 2018:

<i>Years ending December 31,</i>		Amount
2019	\$	2,407,876
2020		1,998,667
2021		1,684,902
2022		1,195,935
2023		859,152
Thereafter		2,206,001
Total future minimum lease payments	\$	10,352,533

14. Employee Benefit Plans

Employee Contribution Plans

Defined Contribution Plans - The Foundation sponsors various defined contribution retirement plans (the "defined contribution plans") covering substantially all of the employees of the Foundation. Participants may contribute a percentage of their compensation on a pretax basis. The Foundation matches a portion of the participants' compensation. Vesting policies are based on the specific defined contribution plan operated either at the National Office or the chartered entity. Total contributions to the defined contribution plans for the years ended December 31, 2018 and 2017 were \$1,117,904 and \$1,119,949, respectively.

Deferred Compensation Plan - The Foundation also maintains a 457(b) nonqualified deferred compensation plan that permits a select group of executive level employees to set aside a portion of salary on a before-tax basis. In addition to voluntary elective deferrals, the Foundation makes non-elective contributions to the plan. At the discretion of the Foundation, participants are allowed to allocate plan contributions and designate beneficiaries. The Foundation's contributions totaled approximately \$35,177 and \$37,592 for the year ended December 31, 2018 and 2017, respectively. All assets under the plan remain part of the Foundation's general assets and are subject to the claims of its creditors. All rights to amounts held under the plan are owned by the Foundation. Therefore, the Foundation reports the assets and related liabilities of the plan in its statements of position. At December 31, 2018 and 2017, the assets and liabilities each totaled \$254,066 and \$116,361, respectively.

Arthritis Foundation, Inc.

Notes to Financial Statements

Defined Benefit Plans

The Foundation has various defined benefit pension plans (the "Plan") covering certain employees. Benefits are based on years of service and compensation. Contributions are determined in accordance with each Plan's provisions. As of December 31, 2018 and 2017, the Foundation has recorded an accrued net pension liability of \$1,254,551 and \$1,167,074, respectively, in relation to the Plan. Due to their relative size in relation to the financial statements of the Foundation, additional disclosures are not included.

15. Commitments and Contingencies

The Foundation has commitments for research awards and grants for future years. The terms of research awards and grants are from one to three years. At December 31, 2018, these commitments were as follows:

<i>Years ending December 31,</i>		Amount
2019	\$	9,429,490
2020		470,000
Total commitments	\$	9,899,490

The Foundation is involved in litigation arising from the normal course of business. Although the ultimate outcome of such matters cannot be predicted with certainty, management believes that the current expected outcome of any such matter will not have a material adverse effect on the Foundation's financial condition as of December 31, 2018.

16. Subsequent Events

The Foundation has evaluated subsequent events for potential recognition and/or disclosure in the December 31, 2018 financial statements through June 26, 2019, the date of the audit report and the date the accompanying financial statements were available to be issued. During this period, no material recognizable subsequent events were identified.